Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study

Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly... ORIGINAL ARTICLE Final Efficacy and Safety Results of Pemetrexed   Continuation Maintenance Therapy in the Elderly from the  PARAMOUNT Phase III Study Cesare Gridelli, MD,* Filippo de Marinis, MD,† Michael Thomas, MD,‡ Kumar Prabhash, MD,§ Claude El Kouri, MD,‖ Fiona Blackhall, MD,¶ Frederique Bustin, MD,# Jean-Louis Pujol, MD,** William J. John, MD, FACP,†† Belen San Antonio, PhD,‡‡ Annamaria Zimmermann, MS,†† Nadia Chouaki, MD,§§ Carla Visseren-Grul, MD,‖‖ and Luis G. Paz-Ares, MD, PhD¶¶ males and patients with a performance status of one in the elderly Introduction: The PARAMOUNT Phase III trial showed that main- subgroup. For elderly patients, the median PFS was 6.4 months for tenance pemetrexed after pemetrexed plus cisplatin induction was pemetrexed and 3.0 months for placebo; the median OS was 13.7 well tolerated and effective for patients with advanced nonsquamous months for pemetrexed and 12.1 months for placebo. For non-elderly non–small-cell lung cancer. Approximately 17% of patients receiv- patients, the median PFS was 4.0 months for pemetrexed and 2.8 ing maintenance therapy in this study were 70 years of age or older. months for placebo; the median OS was 13.9 months for pemetrexed Here we report efficacy and safety results from the PARAMOUNT and 10.8 months for placebo. Elderly patients experienced similar study for elderly (≥70 years) and non-elderly (<70 years) patients. levels http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Final Efficacy and Safety Results of Pemetrexed Continuation Maintenance Therapy in the Elderly from the PARAMOUNT Phase III Study

Journal of Thoracic Oncology , Volume 9 (7) – Jul 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/final-efficacy-and-safety-results-of-pemetrexed-continuation-Pu3dX0XlEq

References (24)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000207
pmid
24926544
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL ARTICLE Final Efficacy and Safety Results of Pemetrexed   Continuation Maintenance Therapy in the Elderly from the  PARAMOUNT Phase III Study Cesare Gridelli, MD,* Filippo de Marinis, MD,† Michael Thomas, MD,‡ Kumar Prabhash, MD,§ Claude El Kouri, MD,‖ Fiona Blackhall, MD,¶ Frederique Bustin, MD,# Jean-Louis Pujol, MD,** William J. John, MD, FACP,†† Belen San Antonio, PhD,‡‡ Annamaria Zimmermann, MS,†† Nadia Chouaki, MD,§§ Carla Visseren-Grul, MD,‖‖ and Luis G. Paz-Ares, MD, PhD¶¶ males and patients with a performance status of one in the elderly Introduction: The PARAMOUNT Phase III trial showed that main- subgroup. For elderly patients, the median PFS was 6.4 months for tenance pemetrexed after pemetrexed plus cisplatin induction was pemetrexed and 3.0 months for placebo; the median OS was 13.7 well tolerated and effective for patients with advanced nonsquamous months for pemetrexed and 12.1 months for placebo. For non-elderly non–small-cell lung cancer. Approximately 17% of patients receiv- patients, the median PFS was 4.0 months for pemetrexed and 2.8 ing maintenance therapy in this study were 70 years of age or older. months for placebo; the median OS was 13.9 months for pemetrexed Here we report efficacy and safety results from the PARAMOUNT and 10.8 months for placebo. Elderly patients experienced similar study for elderly (≥70 years) and non-elderly (<70 years) patients. levels

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Jul 1, 2014

There are no references for this article.